Teva Pharmaceutical Industries ADR (TEVA)

$39.19 +0.66 (1.71%)
Market Cap 44.90B
Revenue (ttm) 17.26B
Net Income (ttm) 1.41B
EPS (ttm) N/A
PE Ratio 18.00
Forward PE 20.28
Profit Margin 8.18%
Debt to Equity Ratio 2.14
Volume 5,521,446
Avg Vol 5,279,392
Day's Range N/A - N/A
Shares Out 1.17B
Stochastic %K 88%
Beta 0.87
Analysts Strong Sell
Price Target $43.00

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel
Armin1971
Armin1971 Sep. 18 at 10:27 AM
$TEVA Sie haben
0 · Reply
NNJATRDR
NNJATRDR Sep. 17 at 3:40 PM
$TEVA break all time high!
0 · Reply
HighT_Trader
HighT_Trader Sep. 17 at 2:56 PM
$TEVA 100%. This volatility is different
0 · Reply
SdotRayborn
SdotRayborn Sep. 17 at 1:36 PM
$TEVA again, whoever has been watching this thing move for years + has to be mind boggled by daily price movement. It’s insane to me how it’s acting. Very strange.
0 · Reply
Contrarian_Dan
Contrarian_Dan Sep. 17 at 1:36 PM
$TEVA
0 · Reply
Hopewisper
Hopewisper Sep. 17 at 1:18 PM
$TEVA Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schiz https://share.google/MnK36VCWoTYFaUm84
0 · Reply
Hopewisper
Hopewisper Sep. 17 at 1:15 PM
$TEVA Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Stra https://share.google/pXm3F7kAtrtdJGi2C
0 · Reply
Orbit100
Orbit100 Sep. 16 at 5:53 PM
$TEVA Any pull back is a fantastic buying opportunity. See you to $45 and over.
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Sep. 16 at 4:46 PM
$TEVA printed a new 52-week high today
0 · Reply
Orbit100
Orbit100 Sep. 16 at 3:37 PM
$TEVA This stock has been upgraded to the target price of $45. Stop trading and hold strong.
0 · Reply
Latest News on TEVA
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Sep 14, 2026, 8:03 AM EDT - 4 days ago

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Sep 10, 2026, 6:04 AM EDT - 8 days ago

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Leerink starts Teva with an Outperform with new strategy ‘clearly bearing fruit’

2026-09-09T12:20:51.000Z - 9 days ago

Leerink starts Teva with an Outperform with new strategy ‘clearly bearing fruit’

Teva initiated with an Outperform at Leerink

2026-09-09T10:11:15.000Z - 9 days ago

Teva initiated with an Outperform at Leerink

Teva Announces Launch of Offering of Senior Notes

Sep 7, 2026, 3:53 AM EDT - 11 days ago

Teva Announces Launch of Offering of Senior Notes

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Sep 4, 2026, 11:30 AM EDT - 14 days ago

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Teva price target raised to $48 from $42 at UBS

2026-09-04T10:15:29.000Z - 14 days ago

Teva price target raised to $48 from $42 at UBS

Teva's immune disorder drug meets main goal in mid-stage trial

Sep 2, 2026, 8:03 AM EDT - 16 days ago

Teva's immune disorder drug meets main goal in mid-stage trial

Teva reports TEV ‘408 study met primary endpoint

2026-09-02T11:40:30.000Z - 16 days ago

Teva reports TEV ‘408 study met primary endpoint

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Sep 2, 2026, 7:03 AM EDT - 16 days ago

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Trump Administration Reaches Drug Pricing Deals With 9 Companies

Aug 31, 2026, 4:53 PM EDT - 17 days ago

Trump Administration Reaches Drug Pricing Deals With 9 Companies

BBIO ONC

Teva to lower cost of select medicines for American patients covered by Medicaid

2026-08-31T20:15:08.000Z - 17 days ago

Teva to lower cost of select medicines for American patients covered by Medicaid

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Aug 31, 2026, 4:07 PM EDT - 17 days ago

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Teva unit bids to acquire neuroscience product from BioXcel Therapeutics

2026-08-28T10:26:39.000Z - 21 days ago

Teva unit bids to acquire neuroscience product from BioXcel Therapeutics

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

Aug 28, 2026, 6:17 AM EDT - 21 days ago

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

BioXcel Therapeutics enters asset sale agreement with Teva

2026-08-28T10:05:11.000Z - 21 days ago

BioXcel Therapeutics enters asset sale agreement with Teva

Aurinia settles patent litigation with Teva

2026-08-19T20:11:02.000Z - 4 weeks ago

Aurinia settles patent litigation with Teva

AUPH

Aurinia Settles Patent Litigation with Teva

Aug 19, 2026, 4:05 PM EDT - 4 weeks ago

Aurinia Settles Patent Litigation with Teva

AUPH

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

2026-08-19T15:16:03.000Z - 4 weeks ago

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

Teva announces FDA acceptance of ecopipam NDA

2026-08-19T12:45:52.000Z - 4 weeks ago

Teva announces FDA acceptance of ecopipam NDA

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Aug 19, 2026, 8:30 AM EDT - 4 weeks ago

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva price target raised to $42 from $40 at Barclays

2026-08-17T10:19:43.000Z - 4 weeks ago

Teva price target raised to $42 from $40 at Barclays

Humana agrees not to reference Teva's Israel ties at US drug trial

Aug 13, 2026, 10:16 AM EDT - 5 weeks ago

Humana agrees not to reference Teva's Israel ties at US drug trial

HUM

Teva seeks to keep Israel ties from jury, cites Gaza war

Aug 6, 2026, 12:22 PM EDT - 6 weeks ago

Teva seeks to keep Israel ties from jury, cites Gaza war

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Jul 29, 2026, 7:42 AM EDT - 7 weeks ago

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Jul 29, 2026, 7:24 AM EDT - 7 weeks ago

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Teva reports Q2 EPS 2c, consensus 11c

2026-07-29T11:22:16.000Z - 7 weeks ago

Teva reports Q2 EPS 2c, consensus 11c

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

Jul 22, 2026, 9:16 AM EDT - 1 month ago

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

AMPH ANIP VTRS

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Jul 9, 2026, 8:45 AM EDT - 2 months ago

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Jun 18, 2026, 4:57 PM EDT - 3 months ago

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Jun 18, 2026, 4:30 PM EDT - 3 months ago

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Jun 11, 2026, 3:03 PM EDT - 3 months ago

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Jun 10, 2026, 12:03 PM EDT - 3 months ago

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Jun 5, 2026, 11:30 AM EDT - 3 months ago

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva to Present at the Goldman Sachs Global Healthcare Conference

Jun 1, 2026, 4:30 PM EDT - 3 months ago

Teva to Present at the Goldman Sachs Global Healthcare Conference

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

May 21, 2026, 12:30 PM EDT - 4 months ago

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18, 2026, 8:30 AM EDT - 4 months ago

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

May 18, 2026, 8:00 AM EDT - 4 months ago

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

TD

Teva to Present at the BofA Securities Health Care Conference

May 4, 2026, 4:30 PM EDT - 4 months ago

Teva to Present at the BofA Securities Health Care Conference

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Apr 29, 2026, 2:22 PM EDT - 4 months ago

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Apr 29, 2026, 7:05 AM EDT - 4 months ago

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Apr 29, 2026, 6:30 AM EDT - 4 months ago

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Apr 15, 2026, 8:00 AM EDT - 5 months ago

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva Releases Q1 2026 Aide Memoire

Mar 19, 2026, 4:30 PM EDT - 6 months ago

Teva Releases Q1 2026 Aide Memoire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Mar 19, 2026, 4:30 PM EDT - 6 months ago

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva to Present at the Upcoming Investor Conferences in March

Feb 24, 2026, 4:30 PM EST - 6 months ago

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Feb 20, 2026, 2:43 PM EST - 6 months ago

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 7 months ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:31 AM EST - 7 months ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 28, 2026, 7:00 AM EST - 7 months ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 27, 2026, 8:00 AM EST - 7 months ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 5:02 PM EST - 8 months ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Why Investors Are So Optimistic on Teva

Jan 12, 2026, 10:46 AM EST - 8 months ago

Why Investors Are So Optimistic on Teva

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 6:00 PM EST - 8 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:00 PM EST - 8 months ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:30 PM EST - 8 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 24, 2025, 8:36 AM EST - 8 months ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Armin1971
Armin1971 Sep. 18 at 10:27 AM
$TEVA Sie haben
0 · Reply
NNJATRDR
NNJATRDR Sep. 17 at 3:40 PM
$TEVA break all time high!
0 · Reply
HighT_Trader
HighT_Trader Sep. 17 at 2:56 PM
$TEVA 100%. This volatility is different
0 · Reply
SdotRayborn
SdotRayborn Sep. 17 at 1:36 PM
$TEVA again, whoever has been watching this thing move for years + has to be mind boggled by daily price movement. It’s insane to me how it’s acting. Very strange.
0 · Reply
Contrarian_Dan
Contrarian_Dan Sep. 17 at 1:36 PM
$TEVA
0 · Reply
Hopewisper
Hopewisper Sep. 17 at 1:18 PM
$TEVA Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schiz https://share.google/MnK36VCWoTYFaUm84
0 · Reply
Hopewisper
Hopewisper Sep. 17 at 1:15 PM
$TEVA Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Stra https://share.google/pXm3F7kAtrtdJGi2C
0 · Reply
Orbit100
Orbit100 Sep. 16 at 5:53 PM
$TEVA Any pull back is a fantastic buying opportunity. See you to $45 and over.
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Sep. 16 at 4:46 PM
$TEVA printed a new 52-week high today
0 · Reply
Orbit100
Orbit100 Sep. 16 at 3:37 PM
$TEVA This stock has been upgraded to the target price of $45. Stop trading and hold strong.
0 · Reply
SdotRayborn
SdotRayborn Sep. 16 at 2:31 PM
$TEVA movement been wild since debut on nyse. 6 years watching this stock and its moving like it has no float. Very insane and interesting to say the least.
0 · Reply
Paulbpaulb
Paulbpaulb Sep. 16 at 1:01 PM
$TEVA 🚀
0 · Reply
SdotRayborn
SdotRayborn Sep. 16 at 12:08 PM
$TEVA they gotta update these charts on Webull Robinhood and here I know for sure. This is literally the chart from Teva on the TASE
0 · Reply
layahoo
layahoo Sep. 15 at 6:36 PM
$TEVA New 52 Week High $39.49 Congrats to the strong-handed investors!
0 · Reply
Hopewisper
Hopewisper Sep. 15 at 5:24 PM
$TEVA Teva reducing debt by around $ 1.5 billion per year over the last 4 years .. Teva having a long + short term debt if $ 16.6/16.9 billion. Short term around $ 4.5 billion ... and at cash and cash equvialent position of $ 3.66 billion. DudeRooster is a shmok...
0 · Reply
NNJATRDR
NNJATRDR Sep. 15 at 1:08 PM
$TEVA will break all time high
0 · Reply
TheDudeRooster
TheDudeRooster Sep. 15 at 11:24 AM
$TEVA I guess having $17B in debt is a good thing these days
1 · Reply
G101SPM
G101SPM Sep. 15 at 10:32 AM
$TEVA $38.71 bid. SELL/Take profit on 5% of long position to reduce net cost to zero. Holding long position at $5.77 before this SELL. https://stocktwits.com/G101SPM/message/663082609
0 · Reply
Hshshhssos
Hshshhssos Sep. 15 at 12:48 AM
$TEVA TerraDumb right now
0 · Reply
Contrarian_Dan
Contrarian_Dan Sep. 14 at 7:26 PM
$TEVA 40s inbound.
0 · Reply
tkstockpicker
tkstockpicker Sep. 14 at 6:57 PM
$TEVA Stupid
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Sep. 14 at 6:46 PM
$TEVA printed a new 52-week high today
0 · Reply